✉news BusinessStartups first seen 2 d ago, last 2 d ago, peak #24
Shionogi to buy rare disease startup IntraBio for $2 billion
Original: Shionogi acquires rare disease startup IntraBio for $2 billion
Japanese pharmaceutical company Shionogi has agreed to acquire IntraBio, a biotech startup focused on rare diseases, in a deal valued at $2 billion. The move signals Shionogi's push to expand its pipeline into rare disease treatments. The acquisition is drawing attention as one of the larger biotech deals targeting niche therapeutic areas.
Why now: Shionogi's $2 billion acquisition of IntraBio is a significant deal in the rare disease biotech space.
Rank over time, top of the chart is #1. 2 snapshots from 2 d ago to 2 d ago.
Evidence
- Shionogi acquires rare disease startup IntraBio for $2 billion · Yahoo Finance
API: https://socialmediatrends-api.osmike.com/v1/trends/1143173